HLB FY 2025 Annual ReportBeta
HLB annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 23, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
HLB FY 2025 Annual Report Analysis
Business Overview
- • KRW 84.17B total revenue in FY2025, with healthcare/bio at 23.4%, composite materials 59.7%, media commerce 16.2%
- • FDA NDA submitted May 2023 for Rivoceranib + Camrelizumab as first-line liver cancer, with ongoing FDA re-review and expected approval efforts in 2025
Management Discussion & Analysis
- • Revenue KRW 84,173M (+23.6% YoY); Operating loss KRW -104,217M (-12.1% YoY); Net loss KRW -235,415M (+117.9% YoY)
- • Shipbuilding segment via subsidiary HLB Ocean Tech sales growth and new Original Archive sales drove revenue increase
Risk Factors
- • KRW 79.6B notional cash flow from HLB Inc. 42nd bond with warrants maturing 2030-11-13 (units: KRW thousand in source table)
- • KRW 0.55B derivative asset from HLB Pep 3rd convertible bond with put option maturing 2028-04-08
HLB FY 2025 Key Financial MetricsDART
Total Assets
KRW 930.2B
▲ +4.8% YoY
Operating Cash Flow
-KRW 92.6B
▲ +19.0% YoY
CapEx
KRW 16.9B
▼ -15.1% YoY
Source: KIFRS consolidated financial data from HLB annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding